Literature DB >> 9886913

The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury.

C K Li1, T J Hoffmann, P Y Hsieh, S Malik, W C Watson.   

Abstract

The Xylum Clot Signature Analyzer (CSA) is an automated, user-friendly, benchtop analyzer that assesses platelet function and coagulation in non-anticoagulated whole blood under physiological flow and temperature conditions. From blood drawn in a single venipuncture, the CSA measures: a) the time for platelets to occlude holes "punched" in a blood conduit (platelet hemostasis time or PHT); b) collagen-induced thrombus formation (CITF) as blood flows in a channel containing a collagen fiber; and c) clotting time (CT). Micrographs show platelet-rich thrombi in the punched holes and on the collagen surface after a run. PHT and CITF increased at lower shear rate, suggesting that shear activation of platelets is involved in hole closure and in collagen-induced thrombus formation. In blood mixed with anti-von Willebrand's factor (vWF) antibodies, anti-GPIb antibodies, aurin tricarboxylic acid (ATA), or anti-GPIIb-IIIa, PHT and CITF were prolonged, further supporting the reflection of platelet function by those parameters. At low shear rate (<1000 sec(-1)), native blood and blood treated with anti-vWF did not have significantly different PHTs or CITFs. At high shear rate (>6000 sec(-1)), the PHT and CITF of the anti-vWF-treated sample were significantly greater than those of the untreated sample. This supports the inhibition of shear-induced activation of platelets by anti-vWF in the CSA. Heparin-treated blood showed significantly longer CT, indicating that coagulation of blood under flow is inhibited by heparin. The CSA thus assess multiple aspects of hemostasis under near-physiological conditions.

Entities:  

Mesh:

Year:  1998        PMID: 9886913     DOI: 10.1016/s0049-3848(98)00163-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions.

Authors:  J J Ferguson; M Zaqqa
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures.

Authors:  H M Hussein; T Emiru; A L Georgiadis; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

3.  The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.

Authors:  Melanie M White; Rajini Krishnan; Teddi J Kueter; Mary V Jacoski; Lisa K Jennings
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

4.  Assays of different aspects of haemostasis - what do they measure?

Authors:  Nahreen Tynngård; Tomas L Lindahl; Sofia Ramström
Journal:  Thromb J       Date:  2015-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.